mechanistic target of rapamycin kinase

Overview

The mechanistic target of rapamycin kinase (mTOR) is a central serine/threonine kinase that integrates growth factor, nutrient, energy, and stress signals to regulate cell growth, metabolism, protein synthesis, autophagy, and survival. It is a core component of the PI3K/AKT/mTOR pathway, and its activity is tightly linked to cellular adaptation in both normal physiology and disease. Because of this broad regulatory role, mTOR is a major biomedical target in oncology, inflammatory disease, metabolic disorders, neurodegeneration, and tissue repair.

Pharmacologically, mTOR is best known as the target of sirolimus and everolimus, which suppress mTOR signaling and are used in several clinical settings. In recent research, mTOR has also been studied in connection with AMPK/mTOR, PI3K/AKT, mTOR-TFEB, and related autophagy and lysosomal pathways, reflecting its role as a signaling hub that can either promote anabolic growth or restrain autophagy depending on cellular context.

Focus of Latest Publications

Recent publications highlight mechanistic target of rapamycin kinase (mTOR) as a central therapeutic target across diverse disease domains, where its inhibition modulates critical cellular pathways. mTOR functions as a negative regulator of autophagy and is activated downstream of the phosphatidylinositol 3-kinase/AKT pathway; its inhibition serves as a strategy to enhance cellular degradation processes and limit pathological remodeling. Studies explored both allosteric inhibitors (such as everolimus and sirolimus) and novel selective inhibitors targeting the unique mTORC2 component SIN1, with the latter approach designed to overcome resistance mechanisms triggered by catalytic inhibitors that indiscriminately block both mTORC1 and mTORC2.

In cancer applications, mTOR inhibition demonstrated therapeutic potential across multiple malignancies. everolimus, an mTOR inhibitor, was evaluated in a phase 2 trial (BIOMEDE) for diffuse intrinsic pontine glioma in combination with radiotherapy, showing significantly reduced treatment toxicity compared to other targeted agents and enhanced efficacy in tumors with mTOR pathway mutations or PTEN loss. Nobiletin, a natural compound, suppressed non-small cell lung cancer cell proliferation by downregulating phosphorylation of the PI3K/AKT/mTOR axis when combined with the HDAC inhibitor vorinostat, while selectively targeting the TRKC protein to promote both apoptosis and autophagy. In pancreatic ductal adenocarcinoma, mTOR exhibited complex temporal dynamics during chemotherapy-induced autophagy, initially becoming inactivated to permit early autophagy but subsequently reactivating alongside persistent autophagy through the JNK1-Beclin-1 pathway—a state exploited therapeutically by combining irinotecan with fatty acid oxidation inhibitors to block this resistance mechanism.

mTOR inhibition emerged as a protective strategy in neurodegenerative and metabolic contexts by promoting autophagy and cellular homeostasis. In osteoporosis, betulinic acid enhanced osteoblast survival against inflammatory injury by increasing AMPK phosphorylation and reducing mTOR phosphorylation, thereby amplifying autophagy markers (LC3b II and Beclin-1) while suppressing the NLRP3 inflammasome pathway. Similarly, platelet-rich plasma-primed bone marrow mesenchymal stem cell-derived exosomes promoted spinal cord injury repair through the miR-29a-3p/PTEN/PI3K/AKT/mTOR axis, suppressing neuronal apoptosis and autophagy to enhance nerve regeneration. In Friedreich's ataxia cardiomyopathy, mTOR hyperactivation was identified as a key driver of lysosomal dysfunction and impaired mitophagy, suggesting that mTOR inhibition might restore cardiac mitochondrial quality control.

mTOR signaling was also implicated in cardiac remodeling, aging, and systemic pathologies. sirolimus and related mTOR inhibitors were proposed for cardiac xenotransplantation to prevent porcine xenograft hypertrophy, suppress missing-self rejection, and address senescence driven by mTOR pathway activation—leveraging evidence that mTOR suppression promotes healthy aging and longevity. In the context of HIV, the mTOR inhibitor DDIT4 was associated with delayed viral rebound after antiretroviral therapy interruption, and metformin was shown to induce DDIT4 expression and suppress HIV in primary immune cells, suggesting repurposing of metabolic drugs to achieve HIV silencing. Across neurodegenerative diseases (Alzheimer's, Parkinson's, Huntington's disease), mTOR inhibitors alongside autophagy enhancers were identified as components of comprehensive therapeutic strategies to mitigate chronic neuroinflammation and protein aggregation, while intermittent fasting was proposed to activate AMPK and sirtuin 1 pathways to inhibit mTOR and promote neuroprotective autophagy. These findings collectively position mTOR as a pleiotropic regulator of autophagy, cellular senescence, and immune function, with selective inhibition emerging as a strategy to avoid feedback resistance mechanisms observed with pan-mTOR inhibitors.

Key Publications

• NEWJun In Silico Discovery of mTOR Inhibitors as Potential Therapeutics for Feline Hypertrophic Cardiomyopathy. (Journal of molecular modeling, 2026, PMID 42371166): "The mammalian target of rapamycin (mTOR) is an atypical serine/threonine protein kinase system that also participates in the control of structural and functional remodeling of the heart in relation to haemodynamic stress and non-hemodynamic stimuli."
• May Platelet-rich plasma-primed bone marrow mesenchymal stem cell-derived exosomes inhibit neuronal apoptosis and autophagy, and promote nerve regeneration via the miR-29a-3p/PTEN/PI3K/Akt/mTOR axis after spinal cord injury. (Journal of molecular histology, 2026, PMID 42165939): "Rescue experiments confirmed that the miR-29a-3p/PTEN/PI3K/Akt/mTOR axis may mediate the regulatory effects of PRP-BMSCs-EXO on neuronal apoptosis, autophagy, and nerve regeneration in SCI."
• Jun Biomedical publication details. (PubMed Database, 2026, PMID 42166642)
• May Betulinic acid alleviates the inflammatory injury of osteoblasts in osteoporosis by augmenting autophagy via the AMPK-mTOR signaling pathway. (International journal of molecular medicine, 2026, PMID 42138188): "In addition, BA could enhance the phosphorylation of AMPK in MC3T3-E1 cells treated with H2O2 and reduce the phosphorylation of mTOR, but this effect could be rescued by Compound C (an AMPK blocker)."
• May Nobiletin inhibits non-small cell lung cancer through TRKC and exhibits a synergistic effect with the HDAC inhibitor. (Chinese journal of natural medicines, 2026, PMID 42062032): "Eukaryotic transcriptome sequencing revealed that the combination treatment primarily inhibits tumor cell proliferation by modulating TRKC protein expression and suppressing phosphorylation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway."
• May New Pathological Insights into Biomarkers for Multimodal Therapeutic Approach in Hepatic Neuroendocrine Tumors: A Detailed Case Report. (In vivo (Athens, Greece), 2026, PMID 42049452): "Current biomarkers for neuroendocrine tumors including chromogranin A, synaptophysin, Ki-67, somatostatin receptors, mammalian target of rapamycin, vascular endothelial growth factor and its receptor, and O 6-methylguanine-DNA methyl transferase are important in diagnosis and treatment of NETs."
• Apr Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial. (Nature medicine, 2026, PMID 42032072): "...mTOR inhibitor everolimus and multitargeted tyrosine kinase inhibitor dasatinib in combination with radiotherapy..."
• Jul Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma. (Cancer research, 2026, PMID 42008004): "Although mTOR and autophagy exert suppressive effects on each other, coactivation of mTOR and autophagy has been observed when PDAC cells begin to regrow after treatment."
• Apr Neuroinflammation, Autophagy, and Neurodegeneration: Mechanisms and Therapeutic Insights. (CNS & neurological disorders drug targets, 2026, PMID 41918200): "we focus on critical pathways, including mTOR and AMPK, that regulate these events and illustrate how their dysregulation may lead to a vicious cycle of inflammation and autophagy dysfunction."
• Apr Sirolimus and Mimetics: Modulator Sine Qua Non for Cardiac Xenotransplantation? (FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026, PMID 41909987): "This is the frequently overlooked "missing self" rejection. It is amenable to inhibition by sirolimus and other mammalian target of rapamycin (mTOR) signaling suppressors."